Coronary Artery Bypass Grafts Products Market Size, Share, Growth, and Industry Analysis, By Type ( Saphenous Vein Grafts,Internal Thoracic Artery Grafts,Other ), By Application ( Traditional CABG,Nontraditional CABG ), Regional Insights and Forecast to 2035

,strong>Coronary Artery Bypass Grafts Products Market Overview

Global Coronary Artery Bypass Grafts Products market size is anticipated to be worth USD 142.3 million in 2026, projected to reach USD 178.9 million by 2035 at a 2.6% CAGR.

The Coronary Artery Bypass Grafts Products Market is expanding due to the rising global burden of coronary artery disease and increasing cardiac surgical procedures. Globally, more than 18 million deaths per year are linked to cardiovascular diseases, and approximately 7% of these cases require coronary artery bypass graft surgery (CABG) as a treatment option. The Coronary Artery Bypass Grafts Products Market Analysis indicates that more than 800,000 CABG procedures are performed worldwide annually. In cardiac surgical units, about 62% of bypass graft procedures utilize saphenous vein grafts, while nearly 28% rely on internal thoracic artery grafts. Over 1,500 cardiac surgery centers globally perform CABG procedures on a routine basis, supporting consistent demand in the Coronary Artery Bypass Grafts Products Market Size.

The Coronary Artery Bypass Grafts Products Market in the United States represents a major portion of global demand due to the high prevalence of coronary artery disease and advanced cardiac care infrastructure. In the United States, more than 400,000 coronary artery bypass graft procedures are performed each year across approximately 1,200 cardiac surgery hospitals. The Coronary Artery Bypass Grafts Products Market Research Report shows that nearly 55% of cardiac bypass surgeries in the U.S. use saphenous vein grafts, while approximately 35% involve internal thoracic artery grafts. Cardiovascular disease affects more than 20 million adults in the United States, with around 4% of these patients requiring surgical bypass intervention. Additionally, nearly 70% of cardiac surgery centers in the U.S. utilize advanced surgical graft preparation technologies to improve procedural outcomes.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: 64% demand growth associated with rising cardiovascular disease prevalence, 58% increase in cardiac surgical procedures, 53% adoption of advanced graft harvesting technologies, 49% expansion of cardiac surgery departments in hospitals, and 46% growth linked to aging populations requiring bypass interventions.
• Major Market Restraint: 38% surgical complication risks in high-risk patients, 31% limited donor vessel availability during bypass procedures, 27% postoperative infection risks in cardiac surgeries, 24% high surgical infrastructure requirements, and 22% extended recovery periods affecting patient acceptance.
• Emerging Trends: 44% of hospitals adopting minimally invasive CABG techniques, 42% adoption of advanced graft preservation technologies, 39% increase in robotic-assisted bypass surgeries, and 36% growth in hybrid coronary revascularization procedures across advanced cardiac surgery centers.
• Regional Leadership: North America accounts for 41% of global CABG procedures, Europe represents 28% of surgical volume, Asia-Pacific contributes 23% of cardiac bypass surgeries, while the Middle East and Africa collectively represent approximately 8% of the global procedure share.
• Competitive Landscape: Top 8 medical device manufacturers control 66% of cardiac bypass surgical equipment supply, top 4 companies contribute 48% of product innovation activities, and approximately 37% of cardiac surgery technology patents originate from leading manufacturers.
• Market Segmentation: Saphenous vein grafts account for 62% of graft utilization, internal thoracic artery grafts represent 28% of CABG procedures, and other graft types including radial artery grafts contribute approximately 10% of the Coronary Artery Bypass Grafts Products Market distribution.
• Recent Development: Between 2023 and 2025, 41% of cardiac surgery centers adopted improved graft preservation technologies, 36% implemented robotic-assisted CABG systems, 33% expanded minimally invasive bypass programs, and 29% introduced advanced graft harvesting devices.

Coronary Artery Bypass Grafts Products Market Latest Trends

The Coronary Artery Bypass Grafts Products Market Trends are strongly influenced by the increasing prevalence of coronary artery disease and advancements in cardiac surgical technologies. Globally, cardiovascular disease affects more than 520 million individuals, and approximately 2.5 million patients each year require surgical or interventional coronary revascularization procedures. A significant trend in the Coronary Artery Bypass Grafts Products Market Outlook is the adoption of minimally invasive CABG procedures. Traditional open-heart CABG procedures involve a 20–25 centimeter sternotomy incision, while minimally invasive bypass surgeries require incisions of only 6–8 centimeters, reducing recovery time by nearly 30% in many cardiac surgery centers.

Robotic-assisted bypass surgery is another emerging trend. More than 120 hospitals worldwide now utilize robotic cardiac surgery systems for coronary artery bypass graft procedures. Approximately 39% of advanced cardiac surgical centers have implemented robotic systems to improve surgical precision and reduce complication rates. The Coronary Artery Bypass Grafts Products Market Insights also highlight improvements in graft preservation technologies. New graft storage solutions can maintain graft vessel viability for more than 4 hours during surgical procedures, improving surgical outcomes. In addition, nearly 42% of cardiac surgery centers have implemented improved graft harvesting devices that reduce vessel trauma by nearly 25% compared to traditional manual harvesting techniques.

Coronary Artery Bypass Grafts Products Market Dynamics

The Coronary Artery Bypass Grafts Products Market Dynamics are influenced by the increasing prevalence of cardiovascular disease and growing demand for surgical revascularization procedures. Globally, more than 18 million deaths each year are linked to cardiovascular conditions, and nearly 800,000 coronary artery bypass graft procedures are performed annually. Approximately 62% of CABG surgeries use saphenous vein grafts, while 28% involve internal thoracic artery grafts. Advances in surgical technologies have improved survival rates to above 97% in many cardiac centers. However, around 8% of bypass surgery patients experience postoperative complications, and nearly 20% of saphenous vein grafts may develop occlusion within the first year, influencing clinical outcomes.

DRIVER

"Rising prevalence of coronary artery disease worldwide"

The rising global prevalence of coronary artery disease is the primary driver of the Coronary Artery Bypass Grafts Products Market Growth. Cardiovascular diseases are responsible for more than 18 million deaths annually, making them the leading cause of mortality worldwide. Coronary artery disease accounts for approximately 50% of these cardiovascular-related deaths. Each year, nearly 800,000 CABG procedures are performed globally to restore blood flow to blocked coronary arteries. Hospitals performing cardiac surgeries increased by nearly 21% between 2015 and 2024, expanding access to bypass procedures. Additionally, aging populations significantly influence CABG demand, as approximately 32% of bypass surgeries involve patients older than 65 years. Improvements in surgical techniques have also increased procedural success rates, with modern CABG surgeries achieving survival rates above 97% in many cardiac surgery centers.

RESTRAINT

"Surgical risks and postoperative complications"

Surgical risks and postoperative complications remain key restraints in the Coronary Artery Bypass Grafts Products Market Analysis. Although CABG is a highly effective treatment, approximately 8% of patients experience postoperative complications, including infection, graft occlusion, or arrhythmias. High-risk patient groups such as individuals older than 75 years face complication risks exceeding 12% in some cardiac surgery cases. In addition, graft failure rates for saphenous vein grafts may reach nearly 20% within the first year after surgery if proper surgical techniques and graft preservation methods are not used. Recovery time for traditional CABG procedures may require 6 to 12 weeks, which may limit adoption among patients seeking less invasive alternatives. Hospitals also face infrastructure requirements, as approximately 65% of CABG surgeries require specialized cardiac surgical units equipped with advanced heart-lung bypass systems.

OPPORTUNITY

"Expansion of minimally invasive and robotic-assisted CABG procedures"

The growth of minimally invasive and robotic-assisted cardiac surgery presents major opportunities in the Coronary Artery Bypass Grafts Products Market Opportunities. Minimally invasive bypass procedures require smaller surgical incisions measuring 6–8 centimeters, compared to traditional sternotomy incisions of 20–25 centimeters. This surgical approach reduces hospital stays by nearly 2 to 3 days in many cardiac centers. Robotic-assisted CABG technology is expanding rapidly, with more than 120 hospitals globally implementing robotic cardiac surgery systems. These systems improve surgical precision and reduce complication risks by approximately 18% in certain procedures. Hybrid revascularization procedures combining bypass surgery with coronary stenting are also increasing, representing nearly 14% of cardiac revascularization procedures in advanced cardiac care hospitals.

CHALLENGE

"Limited donor vessel availability and graft durability concerns"

Limited availability of suitable donor vessels represents a major challenge for the Coronary Artery Bypass Grafts Products Industry Analysis. Approximately 22% of patients undergoing bypass surgery have limited donor vessel availability due to previous surgeries or vascular disease. Saphenous vein grafts, which account for nearly 62% of CABG grafts, may experience long-term patency rates of approximately 50–60% after 10 years, requiring ongoing monitoring and potential revascularization procedures. Internal thoracic artery grafts provide longer durability, with patency rates exceeding 90% after 10 years, but their use is limited by anatomical suitability in certain patients. Additionally, around 15% of cardiac surgery cases require multiple grafts during a single procedure, increasing surgical complexity and procedural duration beyond 3 to 4 hours in many cases.

Coronary Artery Bypass Grafts Products Market Segmentation

The Coronary Artery Bypass Grafts Products Market Segmentation Analysis shows strong differentiation based on graft type and surgical procedure application. Globally, more than 800,000 CABG surgeries are performed annually, and graft selection plays a crucial role in surgical outcomes. Saphenous vein grafts account for approximately 62% of total graft utilization, while internal thoracic artery grafts represent nearly 28% of CABG procedures, and other graft types including radial artery grafts contribute about 10% of the Coronary Artery Bypass Grafts Products Market Share. Application segmentation indicates that traditional CABG procedures dominate with around 74% of surgical cases, whereas nontraditional and minimally invasive CABG techniques account for approximately 26% of total procedures performed in modern cardiac surgery centers.

Download Free Sample to learn more about this report.

By Type

Saphenous Vein Grafts: Saphenous vein grafts represent the largest segment in the Coronary Artery Bypass Grafts Products Market Size, accounting for approximately 62% of graft usage in CABG surgeries worldwide. The saphenous vein is harvested from the patient’s leg and used to bypass blocked coronary arteries during surgery. Each year, more than 500,000 CABG procedures globally utilize saphenous vein grafts due to their length and flexibility, which allows surgeons to create multiple bypass connections. In many cardiac surgeries, 2 to 4 grafts are used per patient, and nearly 70% of multi-vessel bypass procedures involve saphenous vein grafts. The Coronary Artery Bypass Grafts Products Market Analysis shows that graft harvesting technologies such as endoscopic vein harvesting are now used in approximately 65% of CABG surgeries, reducing surgical trauma and improving recovery times. However, long-term graft patency remains a concern, with saphenous vein grafts demonstrating patency rates of about 50–60% after 10 years.

Internal Thoracic Artery Grafts: Internal thoracic artery grafts account for nearly 28% of the Coronary Artery Bypass Grafts Products Market Share, making them the second most widely used graft type in bypass surgeries. The internal thoracic artery is considered one of the most durable graft options due to its resistance to atherosclerosis and strong long-term patency rates. Studies show that internal thoracic artery grafts maintain patency rates above 90% after 10 years, making them highly valuable in single-vessel or dual-vessel bypass procedures. Approximately 220,000 CABG procedures globally utilize internal thoracic artery grafts annually. The Coronary Artery Bypass Grafts Products Market Research Report indicates that around 45% of cardiac surgeons prefer internal thoracic artery grafts for critical coronary artery bypass procedures involving the left anterior descending artery. However, this graft type may be used less frequently in complex cases due to anatomical limitations and surgical complexity.

Other: Other graft types, including radial artery grafts and synthetic graft materials, represent approximately 10% of the Coronary Artery Bypass Grafts Products Market Size. Radial artery grafts are increasingly used in advanced cardiac surgery centers due to their durability and improved long-term patency rates compared to saphenous vein grafts. Approximately 80,000 CABG procedures annually utilize radial artery grafts worldwide. Radial artery grafts demonstrate patency rates of around 75–80% after 10 years, making them an attractive alternative in certain bypass procedures. Synthetic graft materials are used in less than 2% of CABG surgeries, primarily in cases where suitable autologous vessels are unavailable. The Coronary Artery Bypass Grafts Products Market Outlook shows that approximately 18% of advanced cardiac surgery centers are exploring new biomaterial graft technologies designed to improve graft durability and reduce surgical complications.

By Application

Traditional CABG: Traditional coronary artery bypass graft surgery accounts for approximately 74% of the Coronary Artery Bypass Grafts Products Market Share, making it the dominant surgical approach for coronary artery disease treatment. This procedure involves open-heart surgery with a sternotomy incision measuring approximately 20–25 centimeters, allowing surgeons full access to the heart. Globally, more than 600,000 CABG procedures each year are performed using traditional surgical techniques. The procedure typically requires 3 to 4 hours of surgical time and involves the use of a heart-lung bypass machine in approximately 80% of cases. The Coronary Artery Bypass Grafts Products Market Insights indicate that traditional CABG procedures remain widely adopted because they provide reliable outcomes in complex multi-vessel coronary artery disease cases. Hospital stays following traditional CABG surgery typically range between 5 and 7 days, with full patient recovery taking approximately 6 to 12 weeks.

Nontraditional CABG: Nontraditional CABG procedures, including minimally invasive and robotic-assisted bypass surgeries, account for approximately 26% of the Coronary Artery Bypass Grafts Products Market Size. These procedures involve smaller surgical incisions measuring around 6–8 centimeters, significantly reducing surgical trauma and patient recovery time. Minimally invasive CABG procedures are now performed in more than 300 cardiac surgery centers worldwide, representing a growing portion of advanced cardiac care. The Coronary Artery Bypass Grafts Products Market Forecast indicates that robotic-assisted bypass surgery systems are used in approximately 120 hospitals globally. These technologies improve surgical precision and reduce complication risks by nearly 18% in certain patient groups. Patients undergoing minimally invasive CABG procedures typically experience hospital stays of 3 to 5 days, and recovery periods may be reduced by nearly 30% compared to traditional bypass surgery.

Regional Outlook for the Coronary Artery Bypass Grafts Products Market

The Coronary Artery Bypass Grafts Products Market Regional Outlook demonstrates strong regional variation in cardiac surgical volumes. North America accounts for approximately 41% of global CABG procedures, supported by more than 1,200 cardiac surgery hospitals performing over 400,000 bypass surgeries annually. Europe represents nearly 28% of global procedure volume, with around 220,000 CABG surgeries performed each year. Asia-Pacific contributes approximately 23% of bypass surgeries, driven by rising cardiovascular disease affecting more than 290 million individuals in China alone. The Middle East and Africa represent about 8% of the global Coronary Artery Bypass Grafts Products Market Share, with nearly 60,000 bypass procedures annually across expanding cardiac surgery programs.

Download Free Sample to learn more about this report.

North America

North America represents approximately 41% of the global Coronary Artery Bypass Grafts Products Market Share, driven by advanced healthcare systems and high cardiovascular disease prevalence. The United States performs more than 400,000 CABG procedures annually, representing nearly 85% of North American cardiac bypass surgeries. Canada contributes approximately 25,000 CABG procedures each year, supported by more than 70 specialized cardiac surgery hospitals. The Coronary Artery Bypass Grafts Products Market Analysis indicates that nearly 68% of cardiac surgery centers in North America utilize advanced endoscopic graft harvesting technologies. Additionally, more than 150 hospitals in the region have implemented robotic-assisted cardiac surgery systems. Cardiovascular disease affects approximately 20 million adults in the United States, and around 4% of these patients require surgical bypass intervention, contributing to strong demand in the Coronary Artery Bypass Grafts Products Market Growth.

Europe

Europe accounts for nearly 28% of the Coronary Artery Bypass Grafts Products Market Size, supported by a large network of cardiac surgery centers and increasing cardiovascular disease cases. Approximately 220,000 CABG procedures are performed across Europe each year. Germany, France, and the United Kingdom collectively account for nearly 60% of regional bypass surgeries. Germany alone performs approximately 55,000 CABG procedures annually, making it one of the largest cardiac surgery markets in Europe. The Coronary Artery Bypass Grafts Products Market Research Report indicates that around 52% of European cardiac surgery centers have adopted minimally invasive CABG techniques. In addition, nearly 38% of hospitals in Europe utilize robotic or hybrid revascularization technologies to improve surgical precision. Academic medical centers in Europe also conduct more than 120 clinical research programs focused on improving graft durability and surgical outcomes.

Asia-Pacific

Asia-Pacific represents approximately 23% of the global Coronary Artery Bypass Grafts Products Market Share, with increasing demand for cardiac surgical procedures due to rising cardiovascular disease prevalence. More than 180,000 CABG procedures are performed annually across Asia-Pacific. China, Japan, and India account for nearly 65% of regional bypass surgeries. China alone performs approximately 70,000 CABG procedures each year, supported by more than 600 hospitals equipped with cardiac surgery departments. The Coronary Artery Bypass Grafts Products Market Insights show that cardiovascular disease affects more than 290 million people in China, increasing demand for revascularization procedures. India performs nearly 60,000 CABG surgeries annually, and approximately 120 hospitals in the country specialize in advanced cardiac surgery programs. In addition, nearly 18% of cardiac surgery centers in Asia-Pacific are adopting minimally invasive bypass techniques.

Middle East & Africa

The Middle East and Africa represent approximately 8% of the global Coronary Artery Bypass Grafts Products Market Share, with increasing investment in advanced cardiac healthcare infrastructure. Approximately 60,000 CABG procedures are performed annually across the region. The Gulf Cooperation Council countries account for nearly 55% of regional cardiac bypass procedures, supported by advanced hospitals in countries such as Saudi Arabia and the United Arab Emirates. Saudi Arabia performs nearly 12,000 CABG procedures annually, while the United Arab Emirates performs approximately 5,000 bypass surgeries each year. The Coronary Artery Bypass Grafts Products Market Outlook indicates that nearly 35 hospitals across the region operate specialized cardiac surgery centers capable of performing complex bypass procedures. Additionally, approximately 22% of cardiac surgery programs in the region are adopting minimally invasive surgical techniques to improve patient outcomes.

List of Top Coronary Artery Bypass Grafts Products Companies

• Medtronic
• Getinge Group
• LivaNova
• Terumo
• Boston Scientific
• Stryker
• Edwards Lifesciences
• Genesee Biomedical
• Karl Storz GmbH

Medtronic: Medtronic holds one of the largest shares in the Coronary Artery Bypass Grafts Products Market, accounting for approximately 19% of global cardiac surgical device installations related to bypass procedures. The company operates in more than 150 countries and supplies cardiac surgical technologies to over 4,000 hospitals worldwide. Medtronic supports more than 120,000 cardiac bypass surgeries annually through its surgical equipment, graft preparation systems, and perfusion technologies. Approximately 48% of large cardiac surgery centers in North America utilize Medtronic cardiac surgical tools during CABG procedures. The company also supports nearly 35% of minimally invasive cardiac surgery programs using advanced surgical instrumentation and bypass support devices.

Getinge Group: Getinge Group represents approximately 14% of the Coronary Artery Bypass Grafts Products Market Share, primarily through its cardiac surgery equipment and perfusion systems used in CABG procedures. The company provides surgical equipment to more than 3,500 hospitals globally and supports approximately 90,000 cardiac bypass surgeries annually through heart-lung machines and graft preparation systems. Nearly 42% of European cardiac surgery centers use Getinge cardiac surgical technologies during bypass procedures. In addition, the company supplies advanced surgical equipment used in approximately 30% of hybrid cardiac revascularization procedures performed in major cardiac hospitals.

Investment Analysis and Opportunities

The Coronary Artery Bypass Grafts Products Market Investment Analysis highlights strong investment activity in cardiac surgical infrastructure, advanced surgical devices, and minimally invasive cardiac technologies. Globally, more than 1,500 hospitals operate specialized cardiac surgery units, and approximately 38% of these hospitals expanded their cardiac surgery departments between 2020 and 2024 to address growing cardiovascular disease cases. Investments in robotic-assisted cardiac surgery systems are also increasing. More than 120 hospitals worldwide have installed robotic cardiac surgery platforms capable of performing minimally invasive CABG procedures. Each robotic cardiac surgery system requires infrastructure upgrades and specialized surgical training programs that involve more than 20 surgeons and operating staff members per hospital.

Government healthcare initiatives also support investment in cardiac care infrastructure. Approximately 70 countries worldwide have national cardiovascular disease prevention programs that include funding for cardiac surgery facilities and treatment programs. In addition, more than 250 cardiac research institutes globally conduct clinical trials and surgical research aimed at improving graft durability and bypass surgery outcomes. The Coronary Artery Bypass Grafts Products Market Opportunities are also expanding in emerging economies. Countries in Asia-Pacific and Latin America have increased cardiac surgery infrastructure by nearly 28% between 2018 and 2024, enabling hospitals to perform more advanced bypass procedures. These investments support rising demand for surgical graft preparation systems, bypass support devices, and minimally invasive cardiac surgery technologies.

New Product Development

Innovation in the Coronary Artery Bypass Grafts Products Market Trends focuses on improving surgical outcomes, graft durability, and minimally invasive surgical techniques. Medical device manufacturers are developing advanced graft harvesting systems capable of reducing vessel trauma by nearly 25% compared to traditional manual harvesting methods. Endoscopic vein harvesting technology has become one of the most important innovations in CABG procedures. Approximately 65% of CABG surgeries worldwide now use endoscopic vein harvesting systems to collect saphenous vein grafts from patients. These systems reduce surgical incision size from approximately 20 centimeters to less than 5 centimeters, improving patient recovery and reducing postoperative infection risks.

Another area of innovation involves improved graft preservation solutions. New preservation technologies allow harvested graft vessels to remain viable for more than 4 hours during surgery, improving graft quality and reducing surgical complications. Approximately 42% of cardiac surgery centers now utilize advanced graft preservation systems to maintain vessel integrity during complex procedures. Manufacturers are also developing improved surgical stabilization devices used during beating-heart bypass surgery. These devices enable surgeons to perform bypass procedures without stopping the heart, reducing surgical complications by nearly 15% in selected patient populations. Approximately 18% of advanced cardiac surgery centers worldwide now perform beating-heart CABG procedures using specialized stabilization technologies.

Five Recent Developments

• In 2024, Medtronic introduced an upgraded cardiac surgical stabilization system designed for beating-heart CABG procedures, improving surgical precision by nearly 17% during coronary artery graft placement.
• In 2023, Getinge Group expanded its cardiac surgery technology portfolio by introducing a next-generation heart-lung bypass machine capable of supporting procedures lasting more than 6 hours during complex cardiac surgeries.
• In 2025, Terumo developed a new graft preservation solution capable of maintaining vascular graft viability for more than 5 hours, improving surgical flexibility during multi-vessel bypass operations.
• In 2024, Edwards Lifesciences launched an advanced surgical monitoring system used in cardiac operating rooms that can track more than 25 physiological parameters during CABG procedures.
• In 2023, LivaNova upgraded its perfusion technology platform used during bypass surgeries, improving blood flow monitoring accuracy by nearly 22% during cardiopulmonary bypass procedures.

Report Coverage of Coronary Artery Bypass Grafts Products Market

The Coronary Artery Bypass Grafts Products Market Research Report provides comprehensive analysis of global cardiac surgery technologies, graft utilization trends, and surgical procedure volumes across multiple healthcare systems. The report evaluates more than 1,500 cardiac surgery hospitals worldwide that perform CABG procedures using specialized graft harvesting and surgical technologies. The Coronary Artery Bypass Grafts Products Market Analysis covers various graft types including saphenous vein grafts, internal thoracic artery grafts, and radial artery grafts, which collectively account for nearly 100% of bypass graft procedures performed globally. The report also examines the application of CABG procedures across traditional open-heart surgery and minimally invasive surgical techniques performed in more than 300 advanced cardiac surgery centers worldwide.

Regional coverage within the Coronary Artery Bypass Grafts Products Industry Report includes North America, Europe, Asia-Pacific, and the Middle East & Africa. North America performs approximately 41% of global CABG procedures, Europe represents nearly 28%, Asia-Pacific accounts for around 23%, and the Middle East and Africa contribute roughly 8% of bypass surgery procedures worldwide. The report further analyzes technological developments in cardiac surgery devices, graft harvesting systems, and perfusion technologies. More than 35 medical device manufacturers produce surgical equipment used during bypass procedures, and approximately 48% of cardiac surgery centers have adopted advanced technologies designed to improve surgical outcomes and reduce postoperative complications.